Series A of $9.3M led by an unnamed lead investor, with participation from Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital and i&i Biotech Fund. Brings total capital raised to more than $20 million.
About Antiverse
UK-based biotech using AI-driven generative design and in-house labs to discover therapeutic-grade antibodies against traditionally undruggable targets such as GPCRs, ion channels and extracellular CFTR regions.
Cardiff, United Kingdom
Read Company ProfileFrequently Asked Questions
What type of funding round did Antiverse raise?
Antiverse raised a series-a round.
How much did Antiverse raise in its series-a?
Antiverse raised $9,300,000 USD in its series-a.
Who invested in Antiverse's series-a?
The investors in Antiverse's series-a are: Unspecified Lead Investor, Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital, i&i Biotech Fund.
What type of investment was Antiverse's series-a?
Antiverse's series-a was a equity investment.
How will Antiverse use the funds from its series-a?
Antiverse plans to use the funds for: Scale AI-powered antibody discovery platform for pharmaceutical and foundation partners, Support expansion of the company’s internal drug pipeline, Advance lead antibody programmes toward in vivo efficacy studies, Enable collaborative programmes with partners.